[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Yang et al., 2024 - Google Patents

Discovery of Novel 5, 6-Dihydro-4 H-pyrido [2, 3, 4-de] quinazoline Irreversible Inhibitors Targeting Both Wild-Type and A775_G776insYVMA Mutated HER2 Kinases

Yang et al., 2024

Document ID
5031841609311191359
Author
Yang L
Li Y
Du Y
Guo Y
Guo Z
Liu B
Liu J
Liu Y
Niu H
Sun Y
Yan H
Yang Y
Yu S
Zhang Y
Zhang Y
Zheng K
Zheng N
Zhang X
Zhang Q
Hu L
Publication year
Publication venue
Journal of Medicinal Chemistry

External Links

Snippet

HER2 mutations were seen in 4% of non-small-cell lung cancer (NSCLC) patients. Most of these mutations (90%) occur as an insertion mutation within the exon 20 frame, leading to the downstream activation of the PI3K-AKT and RAS/MAPK pathways. However, no targeted …
Continue reading at pubs.acs.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4

Similar Documents

Publication Publication Date Title
Engelhardt et al. Start selective and rigidify: the discovery path toward a next generation of EGFR tyrosine kinase inhibitors
Kettle et al. Structure-based design and pharmacokinetic optimization of covalent allosteric inhibitors of the mutant GTPase KRASG12C
Sheppard et al. Discovery of N-Ethyl-4-[2-(4-fluoro-2, 6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl) phenyl]-6-methyl-7-oxo-1 H-pyrrolo [2, 3-c] pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain
Smith et al. Fragment-based discovery of MRTX1719, a synthetic lethal inhibitor of the PRMT5• MTA complex for the treatment of MTAP-deleted cancers
McAulay et al. Alkynyl benzoxazines and dihydroquinazolines as cysteine targeting covalent warheads and their application in identification of selective irreversible kinase inhibitors
Chen et al. Small-molecule inhibitors directly targeting KRAS as anticancer therapeutics
Henise et al. Irreversible Nek2 kinase inhibitors with cellular activity
Hodges et al. Discovery and structure-based optimization of benzimidazole-derived activators of SOS1-mediated nucleotide exchange on RAS
Zhang et al. Discovery of novel potent VEGFR-2 inhibitors exerting significant antiproliferative activity against cancer cell lines
Singh et al. Design of novel 3-pyrimidinylazaindole CDK2/9 inhibitors with potent in vitro and in vivo antitumor efficacy in a triple-negative breast cancer model
Ward et al. Structure-and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)
Tan et al. Development of dual inhibitors targeting epidermal growth factor receptor in cancer therapy
Shaikh et al. Emerging approaches to overcome acquired drug resistance obstacles to osimertinib in non-small-cell lung cancer
Heinzlmeir et al. Chemical proteomics and structural biology define EPHA2 inhibition by clinical kinase drugs
Nishiguchi et al. Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2 H-pyran-4-yl) oxy)-[3, 3′-bipyridin]-5-yl)-3-(trifluoromethyl) benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
Chumbalkar et al. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR
Bryan et al. Pyridones as highly selective, noncovalent inhibitors of T790M double mutants of EGFR
Balius et al. Quantitative prediction of fold resistance for inhibitors of EGFR
Ju et al. Design and evaluation of potent EGFR inhibitors through the incorporation of macrocyclic polyamine moieties into the 4-anilinoquinazoline scaffold
Turner et al. From fragment to lead: de novo design and development toward a selective FGFR2 inhibitor
Chen et al. Discovery of ddo-2213 as a potent and orally bioavailable inhibitor of the wdr5–mixed lineage leukemia 1 protein–protein interaction for the treatment of mll fusion leukemia
Teuscher et al. Discovery of potent orally bioavailable WD repeat domain 5 (WDR5) inhibitors using a pharmacophore-based optimization
Ensan et al. Targeting ALK2: an open science approach to developing therapeutics for the treatment of diffuse intrinsic pontine glioma
Haffner et al. Discovery of pyrazolocarboxamides as potent and selective receptor interacting protein 2 (RIP2) kinase inhibitors
Stockley et al. Discovery, characterization, and structure-based optimization of small-molecule in vitro and in vivo probes for human DNA polymerase theta